Clene reports positive long-term results from VISIONARY-MS LTE trial for CNM-Au8 in MS

Clene Inc.

Long-term CNM-Au8 treatment showed significant improvement in vision (LCLA) through 35 months, p<0.0001, mean +8.70 letters.
Cognition improved via SDMT through 35 months, p<0.0001, mean +8.03 points.
Global neurological function (mMSFC) improved through 35 months, p=0.018.
No serious adverse events attributed to CNM-Au8; treatment well-tolerated with 94% compliance.
Data presented at ACTRIMS Forum 2024; 55 of 69 eligible participants continued in LTE.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.